The BRECLIM trial

Project description

Breast cancer is treated by a combination of surgery, radiotherapy, and medical treatment including chemotherapy, endocrine and targeted therapies. When distant metastasis beyond local lymph nodes occur, most patients receive oncological treatment and the role of surgery is uncertain. Some reports suggest there might be a survival benefit from resection of metastases in the liver while opponents to surgery argue that there is a lack of evidence and that an operation interrupts oncological treatment.  
 
The purpose of this multicentre randomized clinical trial is to evaluate local treatment for breast cancer liver metastases, compared to systemic oncological treatment only. The primary endpoint is time to death from any cause. The secondary endpoints are three years survival, progression-free survival, median overall survival, breast cancer specific survival and quality of life. The aim is also to evaluate overall safety and predictive factors for survival during oncological and surgical treatment. The overall purpose is to ameliorate treatment for advanced breast cancer. 

 

PhotoIve Van Krunkelsven

Participating sites

Norrlands University Hospital Umeå 
Sahlgrenska University Hospital Gothenburg 
Skane University Hospital Lund 
Akademiska University hospital Uppsala 
University Hospital of Linkoping 
Karolinska University Hospital Huddinge 

Local investigators surgery

Oskar Hemmingsson (Umeå) 
Helena Taflin (Gothenburg) 
Per Sandström (Linköping) 
Bengt Isaksson (Uppsala) 
Christina Villard (Stockholm) 
Bodil Andersson (Lund)

Local investigators oncology

Anne Andersson (Umeå) 
Cecilia Remling (Gothenburg)
Nina Letter Al-Ayoubi (Linköping) 
Henrik Lindman (Uppsala) 
Theodoros Foukakis (Stockholm) 
Farnaz Lindqvist (Lund) 

Trial Committee 

Oskar Hemmingsson (Umeå) 
Malin Sund (Umeå) 
Anne Andersson (Umeå) 
Helena Taflin (Gothenburg) 
Marcus Sundén (Sunderbyn) 
Per Liv (Umeå)